

<b>Name of Finished Drug substance: Fluoxetine Hydrochloride Ph.Eur/BP+IH.</b>			
Manufactured By.		Cadila Pharmaceuticals Limited, Ankleshwar	
Batch No.	20FH170	A.R. No.	20FP1243
Manufacturing Date	SEPTEMBER 2020	Qty. Mfgd.	155.23 Kg.
Expiry Date	AUGUST 2025	Sample Qty.	126.6 gm
Specification No	FPS/239		
Storage condition	Store in a tightly closed container at room temperature. (Not more than 25°C, excursion allowed 15°C to 30°C).		
<b>Certificate of Analysis</b>			
<b>Test</b>	<b>Requirements</b>		<b>Results</b>
Characters: A. Description B. Solubility	A. White or almost white crystalline powder. B. Sparingly soluble in water and in methylene chloride, Freely soluble in methanol.		White crystalline powder. Sparingly soluble in water and in methylene chloride, Freely soluble in methanol.
Identification A. By IR	A. The infrared absorption spectrum obtained from the sample should be concordant with the spectrum obtained from Fluoxetine Hydrochloride working standard. B. Should be responds the chlorides		The infrared absorption spectrum obtained from the sample is concordant with the spectrum obtained from Fluoxetine Hydrochloride working standard. Complies
B. Test for chloride	Solution should be clear and colourless		Solution clear and colourless
Appearance of solution	Between 4.5 and 6.5		6.12
pH	Between - 0.05° and + 0.05°		+0.01°
Optical rotation	Not more than 0.50 % w/w		0.05 % w/w
Water content (By KF)	Not more than 0.10 % w/w		0.06 % w/w
Sulfated ash	Not more than 0.25 % Not more than 0.25 % Not more than 0.15 % Not more than 0.10 %		Not Detected Below Quantification limit Below Detection limit Not Detected
Related substances (By HPLC) Impurity A Impurity B Impurity C Dimethyl amine impurity at RRT about 1.35 Unspecified impurity Total impurities	Not more than 0.10 % Not more than 0.50 %		Below Disregard limit 0.06 %
Assay (By HPLC)	Not less than 98.0 % w/w and not more than 102.0 % w/w of C <sub>17</sub> H <sub>18</sub> F <sub>3</sub> NO.HCl, calculated on the anhydrous basis		99.6 % w/w
Residual solvents (By GC) Benzene Ethyl acetate Toluene	Not more than 1 ppm Not more than 5000 ppm Not more than 100 ppm		Not Detected Not Detected Not Detected
*Acetonitrile (By GC)	Not more than 0.1 %		Not Performed
<b>Additional Test:</b>			
Particle size	90 % less than 50 µ.		90 % particles are 18.2 µ
<b>Remarks:</b> The material complies with respect to the above specifications.			
<b>Statement of Compliance:</b> We, hereby confirm that this batch is manufactured in accordance with current Good Manufacturing Practices.			
<b>* 'Acetonitrile is not used in the manufacturing process' hence need not to be tested.</b>			
	<b>Prepared By</b>	<b>Checked By</b>	<b>Approved By</b>
<b>Name</b>	Mukesh Solanki	Nitin Panchal	Nilkanth Chopade
<b>Designation</b>	Sr.Officer-QA	Asst.Manager-QA	Manager-QA
<b>Signature</b>			
<b>Date</b>	07.10.20	07.10.20	07.10.20

F/QA007/14/13.04.18

Name of Finished Drug substance: Fluoxetine Hydrochloride Ph.Eur/BP+IH.			
Manufactured By.	Cadila Pharmaceuticals Limited, Ankleshwar		
Batch No.	20FH170	A.R. No.	20FP1243
Manufacturing Date	SEPTEMBER 2020	Qty. Mfgd.	155.23 Kg.
Expiry Date	AUGUST 2025	Sample Qty.	126.6 gm
Specification No	FPS/239		
Storage condition	Store in a tightly closed container at room temperature. (Not more than 25°C, excursion allowed 15°C to 30°C).		
Certificate of Analysis			

**Limit of Detection (LOD) and Limit of Quantification (LOQ) table:**

Name of compound	LOD (%)	LOQ (%)
Impurity A	0.001	0.002
Impurity B	0.001	0.003
Impurity C	0.016	0.046
Dimethyl amine	0.007	0.018
Fluoxetine	0.004	0.012

Name of compound	LOD (ppm)	LOQ (ppm)
Ethyl Acetate	0.495	1.500
Benzene	0.050	0.150
Toluene	0.165	0.500

	Prepared By	Checked By	Approved By
Name	Mukesh Solanki	Nitin Panchal	Nilkanth Chopade
Designation	Sr.Officer-QA	Asst.Manager-QA	Manager-QA
Signature			
Date	07-10-20	07-10-20	07-10-20

F/QA007/14/13.04.18